Comparison of two quantitative polymerase chain reaction methods for detecting HER2/neu amplification

Millson, Alison; Suli, Arminda; Hartung, Leah; Kunitake, Steve; Bennett, Ann; Nordberg, Mary C. Lowry; Hanna, Wedad; Wittwer, Carl T.; Seth, Arun; Lyon, Elaine

doi:10.1016/s1525-1578(10)60471-0

Cited by 51HER2/EGFR in Cancer ResearchMolecular Biology Techniques and ApplicationsLung Cancer Treatments and Mutations

Comparison of two quantitative polymerase chain reaction methods for detecting HER2/neu amplification

Open access

Millson, Alison, Suli, Arminda, Hartung, Leah, Kunitake, Steve, Bennett, Ann, Nordberg, Mary C. Lowry, Hanna, Wedad, Wittwer, Carl T. +2 more·2003·The Journal of Molecular Diagnostics

DOI 10.1016/s1525-1578(10)60471-0PMC PMC1907331

Open this paper in CoChat — free account Open PDF

Abstract

Two quantitative polymerase chain reaction (PCR) methods for HER2/neu gene quantification were evaluated for implementation into a clinical laboratory. Assays were developed using sequence-specific hybridization probes to detect a target (HER2/neu) and a reference gene (beta-globin) simultaneously. One method utilizes real-time quantification while the second uses internal competitors and melting curves to quantify the unknown sample. These two methods were evaluated using three cell lines and 97 breast tumor samples. Two hundred ninety-four samples were subsequently evaluated using the real-time quantification and immunohistochemical (IHC) staining. Real-time PCR gave HER2/neu gene doses of 10 for SKBR3 and 2 for T47D while the competitive PCR gave doses of 11 for SKBR3 and 2.2 for T47D. Both methods produced coefficients of variation (CV) of less than 3% for within-run and less than 6% for between-run analysis. Examination of 97 breast tumors found a correlation of r = 0.974 between the two methods. IHC and PCR results agreed for 234 of the subsequent 294 samples analyzed (79% concordance). A subset of ten discrepant samples was microdissected. After microdissection all ten were positive by PCR, thus resolving the discrepancy. Real-time quantification and microdissection is useful clinically for HER2/neu quantification. Its ease of use and broad dynamic range allows screening for amplification of HER2/neu.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s1525-1578(10)60471-0

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

SK-BR-3 gDNA has high levels of HER2 amplification corresponding to the published copy number range of 14-24 copies per diploid genome.
“Analysis of the SK-BR-3 gDNA identified high levels of HER2 amplification that corresponds with the published copy number range (14–24 copies per diploid genome) (41,43–45,47).”
From Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation (2012) · cites this paper as [45]
The Results (p. 4) report high HER2/neu amplification in SKBR3, with a gene dose of 10 relative to the single-copy MRC-5 control; the competitive PCR results (p. 4) give a dose of 11. Our copy does not state the claimed published range of 14–24 copies per diploid genome or explicitly equate its measurements with that range. (LLM, conf=0.84)
Experimental — accuracy not yet measured
T-47D gDNA gave a HER2:RNase P ratio of <2 (3-4 copies per diploid genome).
“T-47D gDNA gave a HER2:RNase P ratio of < 2 (3–4 copies per diploid genome) (43–46).”
From Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation (2012) · cites this paper as [45]
Sample Preparation (p. 2) and Results (p. 4) describe T47D as having approximately four HER2/neu copies, supporting the copy-number portion of the claim. The paper uses β-globin, not RNase P, as its reference gene; Results (p. 4) reports a T47D gene dose of 2, and the β-globin section (p. 4) reports 2.2 by the other method. It therefore does not support a HER2:RNase P ratio below 2. (LLM, conf=0.89)
Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ <i>neu</i> Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · see citing works
Enzymatic Amplification of β-Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle Cell Anemia
Saiki, R. K., Scharf, S., Faloona, F., Mullis, K. B., Horn, G. T., Erlich, H. A., & Arnheim, N. (1985) · Science · doi:10.1126/science.2999980 · Cited by 8,956 · see citing works
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817 · see citing works
Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene
Coussens, L. M., Yang‐Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J. P., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,815 · see citing works
Methods and applications
Hansen, H. M., Hurwitz, W. N., & Madow, W. G. (1953) · Wiley eBooks · Cited by 1,614 · see citing works
Continuous Fluorescence Monitoring of Rapid Cycle DNA Amplification
Wittwer, C. T., Herrmann, M. G., Moss, A. A., & Rasmussen, R. P. (2013) · BioTechniques · doi:10.2144/000114043 · Cited by 1,274 · see citing works
Self-citation
Continuous Fluorescence Monitoring of Rapid Cycle DNA Amplification
Wittwer, C. T., Herrmann, M. G., Moss, A. A., & Rasmussen, R. P. (1997) · BioTechniques · doi:10.2144/97221bi01 · Cited by 1,144 · see citing works
Self-citation
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.
Baselga, J. M., Norton, L., Albanell, J., Kim, Y. M., & Mendelsohn, J. M. (1998) · PubMed · Cited by 996 · see citing works
Rapid Cycle Real-Time PCR: Methods and Applications
Wittwer, C. T. (2001) · Springer eBooks · doi:10.1007/978-3-642-59524-0_1 · Cited by 636 · see citing works
Self-citation
The neu Gene: an erb B-Homologous Gene Distinct from and Unlinked to the Gene Encoding the EGF Receptor
Schechter, A. L., Hung, M., Vaidyanathan, L., Weinberg, R. A., Yang‐Feng, T. L., Francke, U., Ullrich, A., & Coussens, L. M. (1985) · Science · doi:10.1126/science.2992090 · Cited by 518 · see citing works
HER-2/neu amplification predicts poor survival in node-positive breast cancer.
Borg, Å., Tandon, A., Sigurdsson, H., Clark, G. M., Fernö, M., Fuqua, S. A. W., Killander, D., & Wl, M. (1990) · PubMed · Cited by 457 · see citing works
Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
Press, M. F., Pike, M. C., Chazin, V. R., Hung, G., Udove, J. A., Markowicz, M., Danyluk, J., Godolphin, W. J., Sliwkowski, M. X., & Akita, R. W. (1993) · PubMed · Cited by 426 · see citing works
Real-time fluorescence genotyping of factor V Leiden during rapid-cycle PCR
Lay, M. J., & Wittwer, C. T. (1997) · Clinical Chemistry · doi:10.1093/clinchem/43.12.2262 · Cited by 333 · see citing works
Self-citation
Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
Shak, S. (1999) · PubMed · Cited by 288 · see citing works
Untitled work
(1990) · PubMed · Cited by 142 · see citing works
Fusion of a novel gene,ELKS, toRET due to translocation t(10;12)(q11;p13) in a papillary thyroid carcinoma
Nakata, T., Kitamura, Y., Shimizu, K., Tanaka, S., Fujimori, M., Yokoyama, S., Ito, K., & Emi, M. (1999) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199906)25:2 · Cited by 133 · see citing works
Aneusomy 17 in Breast Cancer: Its Role in HER-2/neu Protein Expression and Implication for Clinical Assessment of HER-2/neu Status
Wang, S., Saboorian, M. H., Frenkel, E. P., Haley, B., Siddiqui, M. T., Gokaslan, S. T., Hynan, L. S., & Ashfaq, R. (2002) · Modern Pathology · doi:10.1038/modpathol.3880505 · Cited by 128 · see citing works
Mutation detection using fluorescent hybridization probes and melting curve analysis
Lyon, E. (2001) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.1.1.92 · Cited by 121 · see citing works
Self-citation
The Polymerase Chain Reaction
THOMAS, C. (1993) · Methods in plant biochemistry · doi:10.1016/b978-0-12-461020-0.50012-3 · Cited by 119 · see citing works
Overexpression of the c-erbB-2 protein in human breast tumor cell lines
Hynes, N. E., Gerber, H. A., Saurer, S., & Groner, B. (1989) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240390208 · Cited by 109 · see citing works
Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer.
Giai, M., Roagna, R., Ponzone, R., Bortoli, M. D., Dati, C., & Sismondi, P. (1994) · PubMed · Cited by 89 · see citing works
C-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis
Parkes, H. C., Lillycrop, K. A., Howell, A., & Craig, R. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.9 · Cited by 75 · see citing works
Color Multiplexing Hybridization Probes Using the Apolipoprotein E Locus as a Model System for Genotyping
Bernard, P. S., Pritham, G. H., & Wittwer, C. T. (1999) · Analytical Biochemistry · doi:10.1006/abio.1999.4217 · Cited by 73 · see citing works
Self-citation
Rapid Cycle DNA Amplification
Wittwer, C. T., Reed, G. B., & Ririe, K. M. (1994) · Birkhäuser Boston eBooks · doi:10.1007/978-1-4612-0257-8_15 · Cited by 67 · see citing works
Self-citation
DNA extraction with organic solvents in gel barrier tubes
Thomas, S. M., Moreno, R. F., & Tilzer, L. L. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.13.5411 · Cited by 63 · see citing works
Quantification of HER2/neu gene amplification by competitive pcr using fluorescent melting curve analysis
Lyon, E., Millson, A., Lowery, M. C., Woods, R., & Wittwer, C. T. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.5.844 · Cited by 54 · see citing works
Self-citation
Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin).
Burris, H. A. (2000) · PubMed · Cited by 50 · see citing works
Gene amplification for c-erbB-2, c-myc, epidermal growth factor receptor, int-2, and N-myc measured by quantitative PCR with a multiple competitor template
Sestini, R., Orlando, C., Zentilin, L., Lami, D., Gelmini, S., Pinzani, P., Giacca, M., & Pazzagli, M. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.6.826 · Cited by 44 · see citing works
Mutations of the human MUT S homologue 6 gene in ampullary carcinoma and gastric cancer
Imai, Y., Inoue, T., & Ishikawa, T. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19981123)78:5 · Cited by 7 · see citing works
HER2/neu Gene Amplification Quantified by PCR and Melting Peak Analysis Using a Single Base Alteration Competitor as an Internal Standard
Lyon, E., Millson, A., & Suli, A. (2001) · Springer eBooks · doi:10.1007/978-3-642-59524-0_23 · Cited by 4 · see citing works
Self-citation

Flagged first, then by citations

5 of the 35 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

[12]12. combination with trastuzumab (Herceptin). Semin Oncol 2000, 27: 19-23
[15]15. Persson K, Pandis N, Mertens F, Borg A, Baldetorp B, Killander D, Isola J: Chromosomal aberrations in breast cancer: a comparison between cytogenetics and comparative genomic hybridization. Genes Chromosomes Cancer 1999, 25:115-122

Sorted by citations

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobágyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,139 · see citing works
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology
Bartley, A. N., Washington, M. K., Colasacco, C., Ventura, C. B., Ismaila, N., Benson, A. B., Carrato, A., Gulley, M. L., Jain, D., Kakar, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.4836 · Cited by 465 · see citing works
Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation
Whale, A. S., Huggett, J. F., Cowen, S., Speirs, V., Shaw, J., Ellison, S., Foy, C. A., & Scott, D. J. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks203 · Cited by 453 · see citing works
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
Wang, J., & Xu, B. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0069-2 · Cited by 396 · see citing works
Automated Quantitative Analysis (AQUA) of In Situ Protein Expression, Antibody Concentration, and Prognosis
McCabe, A., Dolled-Filhart, M. P., Camp, R. L., & Rimm, D. L. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji427 · Cited by 292 · see citing works
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology
Bartley, A. N., Washington, M. K., Ventura, C. B., Ismaila, N., Colasacco, C., Benson, A. B., Carrato, A., Gulley, M. L., Jain, D., Kakar, S., et al. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0331-cp · Cited by 254 · see citing works
ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines.
Weaver, D. A., Crawford, E. L., Warner, K. A., Elkhairi, F., Khuder, S., & Willey, J. C. (2005) · Molecular Cancer · doi:10.1186/1476-4598-4-18 · Cited by 171 · see citing works
LightCycler Technology in Molecular Diagnostics
Lyon, E., & Wittwer, C. T. (2009) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2009.080094 · Cited by 109 · see citing works
Self-citation
HER2Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma
Bartley, A. N., Washington, M. K., Ventura, C. B., Ismaila, N., Colasacco, C., Benson, A. B., Carrato, A., Gulley, M. L., Jain, D., Kakar, S., et al. (2016) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw206 · Cited by 72 · see citing works
Stellaris™ fluorescence in situ hybridization (FISH) probes: a powerful tool for mRNA detection
Orjalo, A. V., Johansson, H. E., & Ruth, J. L. (2011) · Nature Methods · doi:10.1038/nmeth.f.349 · Cited by 55 · see citing works
Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assesment in breast cancer
Hauser‐Kronberger, C., & Dandachi, N. (2004) · The Histochemical Journal · doi:10.1007/s10735-004-2186-6 · Cited by 51 · see citing works
Testing for HER2 in breast cancer
Lewis, F. A., Jackson, P., Lane, S., Coast, G., & Hanby, A. (2004) · Histopathology · doi:10.1111/j.1365-2559.2004.01903.x · Cited by 46 · see citing works
Detection of HER2 Amplification in Breast Carcinomas: Comparison of Multiplex Ligation‐Dependent Probe Amplification (MLPA) and Fluorescence In Situ Hybridization (FISH) combined with Automated Spot Counting
Moerland, E., van Hezik, R. L. H. P. M., van der Aa, T. C. J. M., van Beek, M. W. P. M., & van den Brule, A. J. C. (2006) · Analytical Cellular Pathology · doi:10.1155/2006/741586 · Cited by 44 · see citing works
HER2 testing: a review of detection methodologies and their clinical performance
Laudadio, J., Quigley, D. I., Tubbs, R., & Wolff, D. J. (2006) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.7.1.53 · Cited by 42 · see citing works
Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer
Nistor, A., Watson, P. H., Pettigrew, N. M., Tabiti, K., Dawson, A. J., & Myal, Y. (2006) · BMC Clinical Pathology · doi:10.1186/1472-6890-6-2 · Cited by 35 · see citing works
Quantitative PCR – new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/ neu DNA quantification with LightCycler real‐time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization
Schlemmer, B. O., Sørensen, B. S., Overgaard, J., Olsen, K. E., Gjerdrum, L. M. R., & Nexø, E. (2004) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510410002922 · Cited by 33 · see citing works
A Transductionally Retargeted Adenoviral Vector for Virotherapy of Her2/neu-Expressing Prostate Cancer
Magnusson, M. K., Kraaij, R., Leadley, R. M., Ridder, C. M. A. D., van Weerden, W. M., van Schie, K. A., van der Kroeg, M., Hoeben, R. C., Maitland, N. J., & Lindholm, L. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.016 · Cited by 30 · see citing works
Update on HER2 Testing for Breast and Upper Gastrointestinal Tract Cancers
Ross, J. S. (2011) · Biomarkers in Medicine · doi:10.2217/bmm.11.31 · Cited by 28 · see citing works
Reliability and Discriminant Validity of HER2 Gene Quantification and Chromosome 17 Aneusomy Analysis by Real-Time PCR in Primary Breast Cancer
Lamy, P., Nanni, I., Fina, F., Bibeau, F., Romain, S., Dussert, C., Penault-Llorca, F. M., Grenier, J., Ouafik, L., & Martin, P. (2006) · The International Journal of Biological Markers · doi:10.5301/jbm.2008.1088 · Cited by 28 · see citing works
Quantitative analysis of total mitochondrial DNA: Competitive polymerase chain reaction versus real‐time polymerase chain reaction
Bhat, H. K., & Epelboym, I. (2004) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.20024 · Cited by 27 · see citing works
Trastuzumab Activates Allogeneic or Autologous Antibody-Dependent Cellular Cytotoxicity against Malignant Rhabdoid Tumor Cells and Interleukin-2 Augments the Cytotoxicity
Katsumi, Y., Kuwahara, Y., Tamura, S., Kikuchi, K., Otabe, O., Tsuchiya, K., Iehara, T., Kuroda, H., Hosoi, H., & Sugimoto, T. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1661 · Cited by 27 · see citing works
Accurate breast cancer diagnosis through real-time PCR her-2 gene quantification using immunohistochemically-identified biopsies
Mendoza‐Almanza, G., Portillo-López, A., & Olmos-Soto, J. (2012) · Oncology Letters · doi:10.3892/ol.2012.984 · Cited by 25 · see citing works
A Single-Tube Quantitative Assay for mRNA Levels of Hormonal and Growth Factor Receptors in Breast Cancer Specimens
Iverson, A. A., Gillett, C., Cane, P., Santini, C. D., Vess, T. M., Kam-Morgan, L. N. W., Wang, A., Eisenberg, M. T., Rowland, C. M., Hessling, J. J., et al. (2009) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2009.080070 · Cited by 24 · see citing works
Regulation of the translation activity of antigen-specific mRNA is responsible for antigen loss and tumor immune escape in a HER2-expressing tumor model
Han, B.-S., Ji, S., Woo, S., Lee, J. H., & Sin, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-39557-9 · Cited by 23 · see citing works
Microsatellite instability test using peptide nucleic acid probe-mediated melting point analysis: a comparison study
Jang, M., Kwon, Y., Kim, H., Kim, H., Min, B. S., Park, Y., Kim, T. I., Hong, S. P., & Kim, W. K. (2018) · BMC Cancer · doi:10.1186/s12885-018-5127-6 · Cited by 21 · see citing works
Copy Number Analysis of c-erb-B2 (HER-2/neu) and Topoisomerase IIα Genes in Breast Carcinoma by Quantitative Real-Time Polymerase Chain Reaction Using Hybridization Probes and Fluorescence In Situ Hybridization
Murthy, S. K., Magliocco, A. M., & Demetrick, D. J. (2005) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2005-129-39-cnaocn · Cited by 21 · see citing works
Improving validation methods for molecular diagnostics: application of Bland-Altman, Deming and simple linear regression analyses in assay comparison and evaluation for next-generation sequencing
Misyura, M., Sukhai, M. A., Kulasignam, V., Zhang, T., Kamel‐Reid, S., & Stockley, T. L. (2017) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2017-204520 · Cited by 16 · see citing works
Evaluation of HER-2/neu Gene Status in Osteosarcoma by Fluorescence In Situ Hybridization and Multiplex and Monoplex Polymerase Chain Reactions
Willmore‐Payne, C., Holden, J. A., Zhou, H., GUPTA, D. K. D., Hirschowitz, S. L., Wittwer, C. T., & Layfield, L. J. (2006) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2006-130-691-eongsi · Cited by 16 · see citing works
Self-citation
Correlation of HER2 Gene Amplification with Immunohistochemistry in Breast Cancer as Determined by a Novel Monoplex Polymerase Chain Reaction Assay
Willmore‐Payne, C., Holden, J. A., & Layfield, L. J. (2005) · Applied immunohistochemistry & molecular morphology · doi:10.1097/01.pai.0000158400.58030.c4 · Cited by 16 · see citing works
NASBA: a novel approach to assess hormonal receptors and ERBB2 status in breast cancer
Lamy, P., Verjat, T., Paye, M., Servanton, A.-C., Grenier, J., Leissner, P., & Mougin, B. (2005) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2006.002 · Cited by 14 · see citing works
Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab
Cavalloni, G., Sarotto, I., Pignochino, Y., Gammaitoni, L., Migliardi, G., Sgrò, L. G., Piacibello, W., Risio, M., Aglietta, M., & Leone, F. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3283050083 · Cited by 10 · see citing works
An Alternative and Reliable Real-time Quantitative PCR Method to Determine HER2/neu Amplification in Breast Cancer
Egervari, K. L., Tóth, J., Nemes, Z., & Szöllősi, Z. (2009) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e3181907a60 · Cited by 9 · see citing works
Validation of a quantitative flow cytometer assay for monitoring HER-2/neu expression level in cell-based cancer immunotherapy products
Randlev, B., Huang, L., Watatsu, M., Marcus, M., Lin, A., & Shih, S. (2010) · Biologicals · doi:10.1016/j.biologicals.2009.12.001 · Cited by 4 · see citing works
Analysis of the HER2/neu gene amplification in microdissected breast cancer tumour samples.
Seth, R. M., Burger, A. M., & Kahn, H. J. (2006) · PubMed · Cited by 3 · see citing works
MULTIMODALITY TESTING OF HER2/NEU MARKER IN BREAST CANCER: A CORRELATIVE STUDY
Balar, S., Joshi, E., & Desai, U. (2022) · Towards Excellence · doi:10.37867/te1401126 · Cited by 2 · see citing works
Evaluación de tres métodos moleculares para el rastreo e identificación de HER2/neu en pacientes con cáncer de mama
Niño, A. G., & Bernal, B. (2010) · Medicina U.P.B. · Cited by 1 · see citing works
Oncogene amplification as tumor marker in a group of Colombian lung cancer patients
Carrillo, E. F., Arias, Y. R., Perdomo, S. J., Aristizábal, F., Ojeda, P., & Palacios, D. (2009) · Colombia medica · doi:10.25100/cm.v40i2.637 · Cited by 1 · see citing works
Housekeeping gene as a source of calibrator candidate for HER-2 scoring in frozen tissue breast cancer study based on qPCR
RISMAYA, R., Azamris, A., BUDIARTI, S., & Desriani, D. (2017) · Biodiversitas Journal of Biological Diversity · doi:10.13057/biodiv/d180323 · Cited by 1 · see citing works
Assays for Gene Amplification
Kim, C., Song, Y.-K., & Paik, S. (2006) · Humana Press eBooks · doi:10.1385/1-59259-915-x:065
Award Lecture LightCycler Technology in Molecular Diagnostics
Lyon, E., & Wittwer, C. T. (2009)
Self-citation
Gesamt-Genom-Microarray-Analyse und Target-Validierung mittels qPCR / Whole genome microarray analysis and target validation by using qPCR
Klein, H., Gorinevski, D., Hörmann, J., Marschall, C., Mayer, K., & Vanetti, M. (2004) · Journal of Laboratory Medicine · doi:10.1515/labmed.2004.031
Liquid-Based Fluorescence In Situ Hybridization Assay for Detection of ERBB2 Gene Amplification in Patients with Breast Cancer3
Yeh, C.-H., Whitmire, W. A., & Albitar, M. X. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.107607
Evaluación de tres métodos moleculares para el rastreo e identificación de HER2/neu en pacientes con cáncer de mama Evaluation of three molecular methods for tracking and identifying HER2/neu oncogene in breast cancer patients
Niño, A. G., Helena, B., Bernal, A., González, L., & Zuluaga, B. H. A. (2010)
Breast Cancer Stem Cells: Tumourspheres and Implications for Therapy
Morrison, B. J. (2011) · Griffith Research Online · doi:10.25904/1912/1434
Cytochrome P450 2D6 Deletion Genotyping Using Derivative Curve Analysis on the LightCycler
Millson, A., Frank, E. L., & Lyon, E. (2004) · Springer eBooks · doi:10.1007/978-3-642-18840-4_17
Self-citation
HER2 testing
Falzon, M., & Gandy, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-28216-9_2
Amplificación Oncogénica Como Marcador Tumoral en un Grupo de Pacientes con Cáncer Pulmonar
Carrillo, E. F., Arias, Y. R., Perdomo, S. J., Aristizábal, F., Ojeda, P., & Palacios, D. (2009) · TSpace (University of Toronto)
HER2 Testing
Falzon, M., & Gandy, M. (2013) · doi:10.1007/978-1-907673-94-8_2
Data from Trastuzumab Activates Allogeneic or Autologous Antibody-Dependent Cellular Cytotoxicity against Malignant Rhabdoid Tumor Cells and Interleukin-2 Augments the Cytotoxicity
Katsumi, Y., Kuwahara, Y., Tamura, S., Kikuchi, K., Otabe, O., Tsuchiya, K., Iehara, T., Kuroda, H., Hosoi, H., & Sugimoto, T. (2023) · doi:10.1158/1078-0432.c.6516867
Data from Trastuzumab Activates Allogeneic or Autologous Antibody-Dependent Cellular Cytotoxicity against Malignant Rhabdoid Tumor Cells and Interleukin-2 Augments the Cytotoxicity
Katsumi, Y., Kuwahara, Y., Tamura, S., Kikuchi, K., Otabe, O., Tsuchiya, K., Iehara, T., Kuroda, H., Hosoi, H., & Sugimoto, T. (2023) · doi:10.1158/1078-0432.c.6516867.v1
Trisomy 21 Detected by SNP Allele Ratios
Pont-Kingdon, G. A., & Lyon, E. (2004) · Springer eBooks · doi:10.1007/978-3-642-18840-4_18
Self-citation

An Alternative and Reliable Real-time Quantitative PCR Method to Determine HER2/neu Amplification in Breast Cancer
Egervari, K. L., Tóth, J., Nemes, Z., & Szöllősi, Z. (2009) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e3181907a60 · Cited by 9 · see citing works
HER-2/neu gene copy number quantified by real-time PCR: comparison of gene amplification, heterozygosity, and immunohistochemical status in breast cancer tissue
Königshoff, M., Wilhelm, J., Bohle, R. M., Pingoud, A., & Hahn, M. (2003) · Clinical Chemistry · doi:10.1373/49.2.219 · Cited by 63 · see citing works
Detection of HER-2/neu gene amplification in breast carcinomas using quantitative real-time PCR — A comparison with immunohistochemical and FISH results
Kulka, J., Tõkés, A., Kaposi-Novák, P., Udvarhelyi, N., Keller-Pintér, A., Lotz, G., & Schaff, Z. (2006) · Pathology & Oncology Research · doi:10.1007/bf02893412 · Cited by 46 · see citing works
Quantification of Her-2/Neu Gene in Breast Cancer Patients using Real Time-Polymerase Chain Reaction (Q-PCR) and Correlation with Immunohistochemistry Findings
Murad, N. A. A., Razak, Z. A., Hussain, R., Hussain, S. N. A. S., Huat, C. K. C., Aishah, C. M. A. S., Abdullah, N., Muhammad, R., Ibrahim, N., & Jamal, R. A. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.3.1655 · Cited by 10 · see citing works
Current Diagnostic Methods of HER-2/neu Detection in Breast Cancer With Special Regard to Real-Time PCR
Merkelbach‐Bruse, S., Wardelmann, E., Behrens, P., Losen, I., Buettner, R., & Friedrichs, N. (2003) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200312000-00010 · Cited by 34 · see citing works

Authors: Millson, A., Suli, A., Hartung, L., Kunitake, S., Bennett, A., Nordberg, M. C. L., Hanna, W., Wittwer, C. T., Seth, A., & Lyon, E.
Affiliations: ARUP Institute for Clinical and Experimental Pathology (US)
University of Utah (US)
Sunnybrook Health Science Centre (CA)
Corresponding author: Lyon, Elaine
ORCID: Suli, Arminda
Hanna, Wedad
Wittwer, Carl T.
Seth, Arun
Venue: The Journal of Molecular Diagnostics
Publisher: Elsevier BV
Published: 2003-08
Volume: 5
Issue: 3
Pages: 184-190
ISSN: 1525-1578 (ISSN-L)
DOI: 10.1016/s1525-1578(10)60471-0
PMC: PMC1907331
OpenAlex: W2086286786
Cited by: 51
References: 35
Citations by year: 2023: 2 · 2022: 1 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 3 · 2013: 1 · 2012: 2
FWCI: 2.84
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Molecular Diagnostics (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Molecular Biology Techniques and Applications
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords: HER2 amplification, real-time PCR, competitive PCR, breast cancer, immunohistochemistry, tumor microdissection, assay comparison, SKBR3, T47D cells
MeSH terms: Base Sequence, Humans, Polymerase Chain Reaction, DNA Primers, Genes, erbB-2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Comparison of two quantitative polymerase chain reaction methods for detecting HER2/neu amplification

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks